Abstract
We show the effects of the three purine derivatives, caffeine, theophylline, and istradefylline, on the cAMP production of adenylyl cyclase 5 (ADCY5)-overexpressing cell lines. A comparison of cAMP levels was performed for ADCY5 wild-type and R418W mutant cells. ADCY5-catalyzed cAMP production was reduced with all three purines, while the most pronounced effects on cAMP reduction were observed for ADCY5 R418W mutant cells. The gain-of-function ADCY5 R418W mutant is characterized by an increased catalytic activity resulting in elevated cAMP levels, resulting in kinetic disorders or dyskinesia in patients. Based on our findings in ADCY5 cells, a slow-release formulation of theophylline was administered to a preschool aged patient with ADCY5-related dyskinesia. A striking improvement of symptoms was observed, outperforming the effects of caffeine that had previously been administered to the same patient.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00029154
Funding Statement
DFG (RTG 2467, project number 391498659: Intrinsically Disordered Proteins. Molecular Principles, Cellular Functions, and Diseases, RTG 2751: InCuPanC, project number 449501615, INST 271/404-1 FUGG, INST 271/405-1 FUGG, and CRC 1423, project number 421152132). The Federal Ministry for Economic Affairs and Energy (BMWi, ZIM project KK5096401SK0). Region of Saxony-Anhalt. Martin Luther University Halle-Wittenberg (Center for Structural Mass Spectrometry).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University of Leipzig was informed and approved this study. The study has been registered at the DRKS (ID: DRKS00029154).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
